Yarrow Bioscience Inc (YARW)

$41.52 +0.12 (0.29%)
Market Cap 27.64M
Revenue (ttm) 570,000.00
Net Income (ttm) -26.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,645.61%
Debt to Equity Ratio 0.00
Volume 17,600
Avg Vol 24,385
Day's Range N/A - N/A
Shares Out 668,000.00
Stochastic %K 62%
Beta 1.95
Analysts Sell
Price Target $58.00

Company Profile

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Address:
40 10 th Avenue, Floor 7, New York, United States
Latest News on YARW
Yarrow Bioscience reported Q2 EPS ($2.14)

2026-08-17T08:10:56.000Z - 2 days ago

Yarrow Bioscience reported Q2 EPS ($2.14)

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Yarrow Bioscience initiated with a Buy at BTIG

2026-08-03T10:31:21.000Z - 16 days ago

Yarrow Bioscience initiated with a Buy at BTIG

Yarrow Bioscience initiated with a Buy at TD Cowen

2026-07-28T15:05:23.000Z - 22 days ago

Yarrow Bioscience initiated with a Buy at TD Cowen

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

Jul 27, 2026, 7:00 AM EDT - 23 days ago

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

Jul 23, 2026, 4:26 PM EDT - 26 days ago

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Jul 10, 2026, 8:00 AM EDT - 5 weeks ago

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

Dec 17, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 10 months ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 30, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

Jul 2, 2025, 7:45 AM EDT - 1 year ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

VYNE Therapeutics Provides Update on VYN202 Program

Apr 25, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Provides Update on VYN202 Program

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 20, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in March Investor Conferences

Feb 20, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Feb 19, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Jan 6, 2025, 7:30 AM EST - 1 year ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Dec 23, 2024, 7:30 AM EST - 1 year ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 26, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

Jun 13, 2024, 9:02 AM EDT - 2 years ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 8:00 AM EDT - 2 years ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 6, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

May 1, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 27, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 7:45 AM EST - 3 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 7, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Nov 1, 2023, 4:15 PM EDT - 3 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:20 AM EDT - 3 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:05 AM EDT - 3 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Oct 30, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

VYNE Therapeutics to Attend BIO International Convention

May 18, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Attend BIO International Convention

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 4:01 PM EDT - 3 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

May 1, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Apr 19, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 30, 2023, 7:45 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 22, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Mar 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 28, 2023, 4:00 PM EST - 3 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 22, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference